SpliSense

Company Overview

Snapshot

Founded in November 2016, SpliSense operates with 11–50 employees. The company has raised a total of $54.5 million across 5 funding rounds from 6 investors. In June 2026, SpliSense secured up to $13 million from the Cystic Fibrosis Foundation to advance its Phase 2b study for cystic fibrosis.

Business overview

SpliSense is a clinical-stage biotechnology company focused on developing RNA-based treatments for pulmonary diseases, particularly those with unmet needs. The company utilizes clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation to the lungs. SpliSense aims to address the root cause of genetic diseases by targeting specific genetic mutations and modulating protein expression and function, operating within the Health Tech & Life Sciences sector.

Strategic signal

In June 2026, SpliSense secured up to $13 million from the Cystic Fibrosis Foundation to advance its Phase 2b study of SPL84 for cystic fibrosis, following positive results from a Phase 2a trial. This investment signals strong validation for SpliSense's lead ASO product and its potential to significantly improve lung function in cystic fibrosis patients, indicating a positive trajectory towards commercialization and further clinical development.

Company Intelligence Q&A

What was the most recent funding event for SpliSense?

In June 2026, SpliSense secured up to $13 million from the Cystic Fibrosis Foundation to advance its Phase 2b study of SPL84 for cystic fibrosis.

What regulatory designation did SpliSense receive for SPL84 in May 2024?

In May 2024, SpliSense received FDA Fast Track Designation for SPL84 for the treatment of cystic fibrosis.

What were the results of the Phase 2 study of SPL84 in cystic fibrosis?

In September 2025, SpliSense reported positive results from its Phase 2 study of SPL84 in cystic fibrosis, demonstrating an improvement in lung function in approximately 70% of patients.

Which organizations granted Orphan Drug Designation to SPL84-23-1?

In January 2022, the FDA and EMA granted Orphan Drug Designation to SpliSense's SPL84-23-1 for the treatment of cystic fibrosis.

What was the outcome of the EMA's review of SPL84?

In March 2026, SpliSense was granted EMA Early PRIME Designation for SPL84 in cystic fibrosis, recognizing its potential to address an unmet medical need.